The Pharmaceutical Whirlwind: From Weight Loss Wonders to Mind-Altering Medicines, A New Era Unfolds

Biotech's Pulse: Gene-Editing's Leap, Cancer's New Fights, and What's Stirring the Industry

A Pharmaceutical Titan's Bold Bet: Novartis Swallows Avidity in a $12 Billion Quest for Genetic Breakthroughs

The Whisper Becomes a Roar: Why Novartis Needs Avidity’s RNA Revolution, Now More Than Ever

The Biotech Gambit: Novartis Reportedly Eyes Avidity in a High-Stakes Acquisition

The Big Pharma Buzz: Why Novartis Might Be Eyeing Avidity's RNA Magic

The Biotech Dance: Novartis Eyes Avidity in a Blockbuster Bid

Novartis' Cosentyx Shines in Long-Term Trial, Offering Hope for Chronic Joint Pain Sufferers

The Great Pharma Debate: Which Giant Will Dominate Your Portfolio?

Transatlantic Tremors: How US Drug Pricing Reforms Are Reshaping the Global Pharmaceutical Landscape

Amneal Pharmaceuticals Eyes Major Market Entry with Xolair Biosimilar, Pledging Affordable Relief

Novartis Plots Strategic Price Adjustments in US as Trump's MFN Deadline Looms

The Future of Vision: Could Eye Drops Really Replace Your Reading Glasses?

India Delivers Major Blow to Novartis: Blockbuster Heart Drug Entresto Patent Revoked

Novartis Forges Monumental US$5.7 Billion Alliance with Monte Rosa Therapeutics to Revolutionize Drug Discovery